MwanzoVRX • SWX
add
Bausch Health Companies Inc
Bei iliyotangulia
CHF 21.44
Bei za mwaka
CHF 21.44 - CHF 21.44
Thamani ya kampuni katika soko
3.44B USD
Uwiano wa bei na mapato
-
Mgao wa faida
-
Habari za soko
Fedha
Taarifa ya Mapato
Mapato
Mapato halisi
(USD) | Sep 2024info | Mabadiliko Tangu Mwaka Uliopita |
---|---|---|
Mapato | 2.51B | 12.15% |
Matumizi ya uendeshaji wa biashara | 1.27B | 13.29% |
Mapato halisi | -85.00M | 77.51% |
Kiwango cha faida halisi | -3.39 | 79.93% |
Mapato kwa kila hisa | 1.12 | 9.34% |
EBITDA | 866.00M | 8.93% |
Asilimia ya kodi ya mapato | -338.10% | — |
Taarifa ya Hali ya Kifedha
Jumla ya mali
Jumla ya dhima
(USD) | Sep 2024info | Mabadiliko Tangu Mwaka Uliopita |
---|---|---|
Uwekezaji wa pesa taslimu na vipindi vifupi | 719.00M | -5.39% |
Jumla ya mali | 26.54B | -1.94% |
Jumla ya dhima | 26.78B | -1.89% |
Jumla ya hisa | -242.00M | — |
hisa zilizosalia | 367.80M | — |
Uwiano wa bei na thamani | -6.72 | — |
Faida inayotokana na mali | 5.13% | — |
Faida inayotokana mtaji | 6.37% | — |
Mtiririko wa pesa
Mabadiliko halisi ya pesa taslimu
(USD) | Sep 2024info | Mabadiliko Tangu Mwaka Uliopita |
---|---|---|
Mapato halisi | -85.00M | 77.51% |
Pesa kutokana na shughuli | 405.00M | 43.62% |
Pesa kutokana na uwekezaji | -102.00M | 94.60% |
Pesa kutokana na ufadhili | -189.00M | -110.41% |
Mabadiliko halisi ya pesa taslimu | 127.00M | -33.85% |
Mtiririko huru wa pesa | 606.75M | 261.43% |
Kuhusu
Bausch Health Companies Inc. is an American-Canadian multinational specialty pharmaceutical company based in Laval, Quebec, Canada. It develops, manufactures and markets pharmaceutical products and branded generic drugs, primarily for skin diseases, gastrointestinal disorders, eye health and neurology. Bausch Health owns Bausch & Lomb, a supplier of eye health products. Bausch Health's business model is primarily focused on acquiring small pharmaceutical companies and then sharply increasing the prices of the drugs these companies sell.
Valeant was originally founded in 1959, as ICN Pharmaceuticals by Milan Panić in California. During the 2010s, Valeant adopted a strategy of buying up other pharmaceutical companies which manufactured effective medications for a variety of medical problems, and then increasing the price of those medications. As a result, the company grew rapidly and in 2015 was the most valuable company in Canada.
Valeant was involved in a number of controversies surrounding drug price hikes and the use of a specialty pharmacy for the distribution of its drugs. This led to an investigation by the U.S. Wikipedia
Afisa Mkuu Mtendaji (CEO)
Ilianzishwa
1959
Makao Makuu
Tovuti
Wafanyakazi
20,270